The 2013 China Medical Science and Technology Award, hosted by Chinese Medical Association and co-hosted by YRPG, released awards in Beijing on January 8, 2013. 86 awards on medical research results were released, including 8 First Prizes, 25 Second Prizes, 47 Third Prizes, 2 Health Management Prizes, 2 Medical Science Popularization Prizes and 2 Medical Policy Awards.
The China Medical Science and Technology Award was set up in 2001 by Chinese Association as the most authoritative sci-tech award, approved by Ministry of Health and Ministry of Science and Technology. With staunch support from YRPG over the 13 since its establishment, the Award has given 1,029 awards to research achievements in medical science, inspiring medical researchers to work harder to promote China’s medical science and medical and health course.
Before the awarding ceremony, the 2014 Annual Academic Conference was held. Chen Zhu, Vice Chairman of NPC and President of Chinese Medical Association, Shen Weichen, Standing Vice Chairman of China National Science and Technology Association, Liu Qian, Vice Director of National Health and Family Planning Commission, and Xu Jingren, Chairman of YRPG, attended the ceremony and present awards to winners. Chen Zhu also addressed the conference.
Chen Zhu said that there had been numerous top medical research findings 13 years since the establishment of the Award, which was acknowledged by the society and most of the researchers within the medical system and had positive social feedback. He hoped that more medical researchers should work harder to explore, catch up and create more results, giving full play to the Award, promoting medical science and technology and translating more medical results into benefits for the people’s well-being. Chen Zhu acknowledged YRPG’s staunch social responsibility and values of “seeking progress all the time and protecting all human beings” and “quality, innovation, benefit and endeavor”, and the company’s quality products to help with people’s health.
Xu Jingren said that it was incumbent on YRPG to care about China’s medical and health cause and support the medical science progress. YRPG has always been prioritizing quality of drugs and social responsibility, and has always living up to its commitment by giving the newest products with best quality and effect. In the future, Xu Jingren said, YRPG would continue to sponsor the appraisal of China Medical Science and Technology Award so that it could contribute more to the progress of medical science and China’s medical and health cause and at the same time encourage more researchers to yield better fruits.
As a pioneer of China’s national pharmaceutical industry, YRPG has always been valuing social responsibility, repaying the society and caring for health of the public. It has been a sole sponsor of China Medical Science and Technology Award for over 13 years and a loyal supporter of China’s medical science progress, winning extensive acknowledgement. The company’s comprehensive strength was among China’s top five pharmaceutical companies for 10 consecutive years. It was among the top three pharmaceutical companies for four consecutive years since 2009. The company has been the largest winners of QC results for over 9 years. The company also has won awards for its creditworthiness, social responsibility and research and development. In 2013 the company was No.1 chemical pharmaceutical company in China and had passed GMP certification two years ahead of schedule.